ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled Phase II trial

被引：22

作者：

Herbst, R

Johnson, B

Rowbottom, J

Fidias, P

Lu, C

Prager, D

Roubec, J

Csada, E

Dimery, I

Heymach, J

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] AstraZeneca, Macclesfield, Cheshire, England

[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[6] Univ Ostrava, Univ Hosp Ostrava, CZ-70852 Ostrava, Czech Republic

[7] Univ Szeged, Szeged, Hungary

[8] AstraZeneca, Wilmslow, Cheshire, England

来源：

关键词：

D O I：

10.1016/S0169-5002(05)80234-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S36

页数：2